mFluiDx's SIMPLE CHIP™ revolutionizes molecular testing with pre-patterned amplification initiators, digital plasma separation, and on-chip pumping powered by a vacuum battery, all protected by a comprehensive patent portfolio.
- General Details
The technology developed here revolutionizes point-of-care molecular tests. It enables PCR panel equivalent tests at the cost and simplicity level of rapid antigen tests. This advancement can replace current gold standards in infectious disease testing, which are dominated by rapid antigen tests and PCR. Moreover, the secondary patent portfolio holds critical importance due to potential infringement by existing market leaders. The patents within this portfolio could serve as prior art, potentially invalidating those patents.
Benefits for Interested Parties
Interested parties would greatly benefit from adopting this advanced technology. It offers a significant advantage over competitors by potentially disrupting their centralized testing business model. Additionally, manufacturers of rapid antigen tests, such as at-home COVID tests, could benefit from this technology. Failure to adopt molecular technology could render rapid antigen testing obsolete in a few years.
If you are interested in mFluiDx, please visit this link.
- Patent Portfolio
Intellectual Property (IP) & Assets for Sale or License
The IP and assets available for sale include:
mFluiDx Omnibus patent portfolio:
- US Application No. 63/579849, ATTY.DOCKET.NO- 4352-P1 US.PRO – Entitled “Consumable microfluidic molecular diagnostic devices, reader systems, roll-to-roll and other methods of manufacturing”; Inventors: Erh-Chia Yeh, Todd Wallis
This is a very extensive omnibus patent, with the PCT draft already finished and designed to be split into 10+ patents. The omnibus PCT draft comprises over 200 pages and holds significantly more weightage than issued patents.
The PCT draft covers multiple elements of mFluiDx, allowing for greater flexibility in licensing and commercialization strategies. The draft discusses SIMPLE chip systems offering on-site molecular diagnostics with PCR-like sensitivity and specificity, enabling concurrent testing of multiple pathogens within minutes at a lower cost compared to traditional PCR testing. These systems utilize a compact design comprising raised portions forming a fluidic circuit between coupled layers.
mFluiDx Secondary Patent Portfolio:
- Patent Cooperation Treaty Publication no. WO 2015/021425 A1 – Entitled “Digital fluid sample separation apparatus and methods for one-step quantitative sample analysis”
- Chinese Issued Patent no. 105,531,591 – Entitled “Digital fluid sample separation equipment and the method for quantifying sample analysis for a step”
- Chinese Abandoned Patent no. 109,136,062 – Entitled “Digital fluid sample separation equipment and the method for quantifying sample analysis for a step”
- EP Patent no. 3,030,908 – Entitled “Digital fluid sample separation apparatus and methods for one-step quantitative sample analysis”
- U.S. Patent no. 10,589,270 – Entitled “Digital fluid sample separation apparatus and methods for one-step quantitative sample analysis”
- U.S. Patent no. 9,737,888 – Entitled “Proximal degas driven microfluidic ”
- Patent Cooperation Treaty Publication no. WO 2016/044532 A1 – Entitled “Vacuum battery for portable microfluidic pumping”
- EP Patent no. 3,194,073 – Entitled “Vacuum battery for portable microfluidic pumping”
- Chinese Issued Patent no. 106,687,216 – Entitled “Vacuum battery for portable microfluidic pumping”
- U.S. Patent no. 9,970,423 – Entitled “Vacuum battery for portable microfluidic pumping”
- U.S. Patent no. 10,864,517 – Entitled “Vacuum battery for portable microfluidic pumping”
Also for sale or license are all trade secrets, manufacturing equipment, design files, and prototypes related to the IP, of which assets there is considerable depth.
- Pricing, Data Room Access & Additional Details
Other Publicly Data Room Materials Are Available at: Link to VIP-3295 Public Data Room – mFluiDx
- Executive Summary
- Other Introductory Material(s)
- Patents and Applications
- Patent File Histories
- Patent Filing Receipts
- Non-Disclosure Agreement Draft to access more files listed below
Additional Materials (available upon signing mutual non-disclosure agreement):
- Due Diligence Review
- Docket Listing of Patents and Applications
- Patent and Application PDFs
- Detailed Description of Portfolio
- Potential Licensees and Related Entities
- Additional Information
- EOU Analysis
- Third-Party Market Valuations
- Inventor and University Licensing office documents
- Previous fund raising materials
- mFluiDx- Point-of-Care Molecular test – the “SIMPLE CHIP” Benefits
Proof of concept and working prototypes may be available.
Contact sales@vibrantip.com for pricing guidance, data room access, and additional information.
- Additional Information
Pricing guidance for this transaction may be available. All parties interested in the IP above are authorized to contact Spencer Rogers at Vibrant IP, LLC at spencer@vibrantip.com and 415-997-9772.
